Humana Inc (NYSE:HUM) has received a consensus recommendation of “Buy” from the twenty-four analysts that are covering the stock, MarketBeat reports. Twelve research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $257.90.
HUM has been the topic of a number of research analyst reports. Credit Suisse Group cut their price target on Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. ValuEngine cut Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. BMO Capital Markets increased their price target on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. Jefferies Group restated a “hold” rating and set a $257.00 price target on shares of Humana in a report on Friday, October 13th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $242.00 price target (down from $245.00) on shares of Humana in a report on Thursday, November 9th.
In other news, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the completion of the sale, the vice president now directly owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the transaction, the senior vice president now owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,115 shares of company stock valued at $2,501,627. Insiders own 0.80% of the company’s stock.
Shares of Humana (NYSE:HUM) opened at $258.36 on Friday. Humana has a twelve month low of $186.25 and a twelve month high of $264.56. The company has a market capitalization of $35,897.88, a P/E ratio of 20.33, a P/E/G ratio of 1.66 and a beta of 0.88. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $13.41 billion. During the same period in the prior year, the business posted $3.18 earnings per share. The firm’s revenue was down 3.0% on a year-over-year basis. equities analysts predict that Humana will post 11.63 EPS for the current fiscal year.
Humana announced that its Board of Directors has initiated a stock repurchase plan on Thursday, December 14th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the insurance provider to purchase shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend is Thursday, December 28th. Humana’s dividend payout ratio is presently 12.59%.
WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/05/humana-inc-hum-receives-average-recommendation-of-buy-from-analysts.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.